Drug Database
Back to search

Japan· JP-6149002F1029

ロキシスロマイシン

A roxithromycin product containing ロキシスロマイシン, registered in Japan by サノフィ, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

On Japan’s NHI price listATC J01FA06

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedロキシスロマイシンATCJ01FA06REGISTER NO.JP-6149002F1029PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ロキシスロマイシンAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Roxithromycin is registered in 12 of 19 countries.

Countries holding a registration under ATC J01FA06 (roxithromycin), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 7 of them publish a price we can compare per daily dose
Search roxithromycin products by name

Roxithromycin · ATC J01FA06

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Italyprice
  • Japan
  • Norwayprice
  • Polandprice
  • Sweden
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of roxithromycin costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), the median price runs from $1.20 in France to $2.73 in Italy — a ×2.3 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Roxithromycin · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

  • IT Italy$2.73
  • FR France$1.20
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

MHLW / PMDA (Japan)
Active substance
ロキシスロマイシン
Manufacturer
サノフィ
Country
Japan (JP)
ATC code
J01FA06
ATC class
Roxithromycin
Defined daily dose
0.3 g, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

50 interactions on record for roxithromycin.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check roxithromycin against other medicinesHow interaction checks work

Roxithromycin · interactions on record

50 records

50 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Roxithromycin in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All roxithromycin products

Authorised across Europe · EMA

The same active substance is authorised in 15 EEA countries. Names it is sold under:

  • Austria · Roxithromycin +pharma, Roxithromycin Sandoz
  • Bulgaria · Роксистад
  • Cyprus · Tirabicin
  • Czechia · Roxithromycin Ratiopharm
  • Germany · Roxi, Roxi 150
  • Denmark · Roximstad, Roxithromycin Medical Valley
  • Spain · Roxitromicina Sandoz
  • Finland · Roxithromycin Sandoz
  • France · Roxithromycine Arrow, Roxithromycine Biogaran
  • Greece · Macrolid-S, Nirox
  • Hungary · Roxithromycin Ratiopharm
  • Italy · Assoral, Rulid
  • Malta · Tirabicin
  • Poland · Rolicyn
  • Sweden · Roximstad, Roxon

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3f6089d6-78f0-49e2-b61d-054a3d48c0f2
GET /v1/drugs/3f6089d6-78f0-49e2-b61d-054a3d48c0f2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "１５０ｍｇ１錠",
  "marks": "局",
  "source": "mhlw",
  "remarks": null,
  "yj_code": "6149002F1029",
  "category": "内用薬",
  "price_yen": 18.7,
  "generic_name": "ロキシスロマイシン",
  "product_name_jp": null,
  "therapeutic_class": "6149",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about roxithromycin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console